Advertisement

Topics

Alpha LIduronidase IDUA or EC 3.2.1.76 Pipeline Review, H1 2018 [Report Updated: 12062018] Prices from USD $3500

13:43 EDT 12 Aug 2018 | BioPortfolio Report Blog

Alpha LIduronidase IDUA or EC 3.2.1.76 Pipeline Review, H1 2018


Summary


According to the recently published report 'Alpha LIduronidase IDUA or EC 3.2.1.76 Pipeline Review, H1 2018'; Alpha LIduronidase IDUA or EC 3.2.1.76 pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.


Alpha LIduronidase IDUA or EC 3.2.1.76 Alpha Liduronidase is an enzyme encoded by IDUA gene. It hydrolyzes the terminal alphaLiduronic acid residues of two glycosaminoglycans, dermatan sulfate and heparan sulfate. Mutations in this gene that result in enzymatic deficiency lead to the autosomal recessive disease mucopolysaccharidosis type I MPS I.


The report 'Alpha LIduronidase IDUA or EC 3.2.1.76 Pipeline Review, H1 2018' outlays comprehensive information on the Alpha LIduronidase IDUA or EC 3.2.1.76 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.


It also reviews key players involved in Alpha LIduronidase IDUA or EC 3.2.1.76 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders which include indications Mucopolysaccharidosis I MPS I Hurler Syndrome .


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Alpha LIduronidase IDUA or EC 3.2.1.76

The report reviews Alpha LIduronidase IDUA or EC 3.2.1.76 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Alpha LIduronidase IDUA or EC 3.2.1.76 targeted therapeutics and enlists all their major and minor projects

The report assesses Alpha LIduronidase IDUA or EC 3.2.1.76 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Alpha LIduronidase IDUA or EC 3.2.1.76 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Alpha LIduronidase IDUA or EC 3.2.1.76

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Alpha LIduronidase IDUA or EC 3.2.1.76 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Alpha LIduronidase IDUA or EC 3.2.1.76 Pipeline Review, H1 2018 [Report Updated: 12062018] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Alpha LIduronidase IDUA or EC 3.2.1.76 Pipeline Review, H1 2018 [Report Updated: 12062018] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...